Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (242)	5/2/2001 12:37:18 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Pharma 1Q Loss 14c/Share Dow Jones Newswires Vion Pharmaceuticals Inc. - New Haven, Conn. 1st Quar March 31: 2001 2000 Revenue $144,479 $198,203 Net income (3,726,025) (2,719,804) Avg shrs 26,176,637 19,739,294 Shr earns Net income (.14) (.16) Figures in parentheses are losses. Vion Pharmaceuticals Inc. (VION) said it has enough cash to complete already scheduled Phase I and Phase II clinical trials. Vion Pharmaceuticals is a biotechnology company developing cancer treatments. Company Web site: vionpharm.com